BioMerieux rapid microbial identification (ID) and antibiotic susceptibility testing
Inactive on SAM.gov — responses were due 12 Oct 2026 · Unrestricted (full and open) · Defense Health Agency (DHA), DoD · JBSA Lackland, TX · NAICS 325413 · Solicitation HT940827Q0003
Following NAICS 325413? Get new solicitations in it by email as they post — no account needed.
SAM.gov marked this notice inactive — responses were due 12 October 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
Likely sole source (FedSift estimate from the notice text) — confirm on SAM.gov before investing in a bid
Get new NAICS 325413 solicitations by email
This one has closed. We'll email you when new NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
NOTICE OF INTENT TO SOLE SOURCE The Wilford Hall Ambulatory Surgical Center, Lackland MDTS/Laboratory Flight s intends to award a sole source contract with bioM rieux, Inc/, to procure a fully automated microbiology instrument that performs rapid microbial identification (ID) and antibiotic susceptibility testing via utilization systems VITEK 2 60, AST, VC-VITEK, and VC-BACT/ALERT VIRTUO systems with MAESTRIA data management. which includes all necessary reagents and comprehensive maintenance services for the Medical Treatment Facility (MTF) Wilford Hall. The Period of Performance is for one (1) year beginning 1 November 2026 through 31 October 2027 in the amount of $135.373.31. The contractor shall deliver the following crucial elements: Vitek2 and BacT/ALERT 3D with Myla Software, 3.1. System Capabilities - Fully automated immunoassay platform utilizing a solid-phase methodology for allergen-specific IgE detection. Capability to perform simultaneous testing of multiple allergens and allergen components from a single patient sample, VTK2 20CARDS GP, GN, YST, NH, ANC, AST-N809, GP67, YS09, VTK2 PIP/DIL. Quantitative measurement of allergen-specific IgE antibodies. Minimal interference from othermunoglobulins (e.g., IgG). Dimensions: (H/W/D): 215 x 183 x 105 cm, 3.2. Performance Requirements. High-throughput capability supporting large-scale laboratory operations. Ability to produce 240 tests per hour with first result available in 100 minutes followed by one every 15 seconds. Interested sources with the demonstrated capability to meet all of the technical requirements outlined in this notice are invited to submit, in writing. Responses must include clear and convincing evidence that competition would be beneficial to the Government and would not be cost or schedule prohibitive. Respondents are responsible for appropriately marking any proprietary information. Responses will not be returned. This synopsis/notice of intent to sole source is issued in accordance with Federal Acquisition Regulation (FAR) Revolutionary FAR Overhaul (RFO) 5.101 and 12.102 and will be posted for 5 days. Response Due Date: October 12, 2026 by 12:00 PM (CST) Submit to: Contracting Officer: Joe D. Wells at joe.d.wells3.civ@health.mil.
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
